Details

Autor(en) / Beteiligte

• Terazawa, Tetsuji
• Kato, Takeshi
• Goto, Masahiro
• Ohta, Katsuya
• Satake, Hironaga
• Noura, Shingo
• Kagawa, Yoshinori
• Kawakami, Hisato
• Hasegawa, Hiroko
• Yanagihara, Kazuhiro
• Shingai, Tatsushi
• Nakata, Ken
• Kotaka, Masahito
• Hiraki, Masayuki
• Konishi, Ken
• Nakae, Shiro
• Sakai, Daisuke
• Kurokawa, Yukinori
• Shimokawa, Toshio
• Tsujinaka, Toshimasa
• Satoh, Taroh

Titel

The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results

Ist Teil von

• The oncologist (Dayton, Ohio), 2023-07, Vol.28 (7), p.e565-e574

Ort / Verlag

US: Oxford University Press

Erscheinungsjahr

2023

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Abstract Background We previously reported the response rate of a phase II OGSG1602 study on panitumumab in chemotherapy-naive frail or elderly patients with RAS wild-type unresectable colorectal cancer (CRC) [Terazawa T, Kato T, Goto M, et al. Oncologist. 2021;26(1):17]. Herein, we report a survival analysis. Methods Patients aged ≥65 years and considered unsuitable for intensive chemotherapy or aged ≥76 years were enrolled. Primary tumors located from the cecum to the transverse colon were considered right-sided tumors (RSTs); those located from the splenic flexure to the rectum were considered left-sided tumors (LSTs). Results Among the 36 enrolled patients, 34 were included in the efficacy analysis, with 26 and 8 having LSTs and RSTs, respectively. The median progression-free survival (PFS) and overall survival (OS) were 6.0 [95% CI, 5.4-10.0] and 17.5 months (95% CI, 13.8-24.3), respectively. Although no significant differences existed in PFS between patients with LST and RST {6.6 (95% CI, 5.4-11.5) vs. 4.9 months [95% CI, 1.9-not available (NA), P = .120]}, there were significant differences in OS [19.3 (95% CI, 14.2-NA) vs.12.3 months (95% CI, 9.9-NA), P = .043]. Conclusion Panitumumab showed favorable OS in frail or elderly patients with RAS wild-type CRC and no prior exposure to chemotherapy. Panitumumab may be optimal for patients with LSTs (UMIN Clinical Trials Registry Number UMIN000024528). This article presents a survival analysis of the phase II OGSG1602 trial on panitumumab in chemotherapy-naive frail or elderly patients with RAS wild-type unresectable colorectal cancer.